Search Results
Your search for ,foR matches 32802 pages
Showing 13601 - 13650MONARCH 2: Interim Analysis of Overall Survival With Abemaciclib/Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer
As reported in JAMA Oncology by George W. Sledge, Jr, MD, and colleagues, an interim analysis of overall survival in the phase III MONARCH 2 trial has shown a significant advantage for abemaciclib plus fulvestrant vs fulvestrant alone in women with advanced hormone receptor–positive, HER2-negative...
Leydig Cell Failure and Dysfunction and Associated Adverse Health Outcomes in Male Survivors of Childhood Cancer
In a retrospective analysis from the St. Jude Lifetime Cohort Study reported in the Journal of Clinical Oncology, Chemaitilly et al identified the prevalence of and risk factors for failure and dysfunction of Leydig cells, which are responsible for testosterone secretion, and associated adverse...
Panitumumab Plus Modified FOLFOXIRI for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
In the German phase II VOLFI trial reported in the Journal of Clinical Oncology, Modest et al found that panitumumab plus modified FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) used as first-line therapy improved the objective response rate in patients with RAS wild-type...
Contrast-Enhanced Ultrasound May Help to Predict Cirrhotic Nodule Transformation to Hepatocellular Carcinoma
An article published by Lin et al in the American Journal of Roentgenology has identified sonographic biomarkers that may predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma. Lead investigator Manxia Lin, MD, of...
Palliative Care Bill Unanimously Approved by U.S. House of Representatives
On October 28, the U.S. House of Representatives unanimously approved the Palliative Care and Hospice Education and Training Act (PCHETA). The bipartisan bill would increase federal research funding for palliative care—including pain and symptom management—and would establish palliative care...
ASCO National Cancer Opinion Survey: Cancer Prevention, E-Cigarette, and End-of-Life Knowledge Gaps Reported
One in four Americans say they incorporate cancer prevention into their daily lives, according to ASCO’s third annual National Cancer Opinion Survey, despite research showing that as many as half of all cancer cases are preventable. The survey found low levels of awareness of known cancer risk...
CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC
As reported in The Lancet by Luis Paz-Ares, MD, and colleagues, an interim analysis of the phase III CASPIAN trial has shown an overall survival benefit with the addition of durvalumab to platinum (either cisplatin or carboplatin)/etoposide chemotherapy in the first-line treatment of...
Pembrolizumab for Patients With Advanced Adrenocortical Carcinoma
In a single-center phase II study reported in the Journal of Clinical Oncology, Raj et al found that pembrolizumab showed activity in advanced adrenocortical carcinoma. Study Details Thirty-nine patients with advanced adrenocortical carcinoma were enrolled in the study between February 2016 and...
Global Burden of Pancreatic Cancer From 1990–2017
The incidence and mortality rates of pancreatic cancer have increased in 195 countries and territories over a 27-year period, according to a systematic analysis performed within the Global Burden of Disease Study 2017 and published in The Lancet Gastroenterology & Hepatology. The study is the...
Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer
In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing the duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...
Relapse-Free Survival After Vismodegib Discontinuation in Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma
In a French retrospective study reported in the Journal of Clinical Oncology, Herms et al found that long-term response is frequently maintained in patients discontinuing vismodegib after complete remission of locally advanced basal cell carcinoma, and that responses can be achieved with vismodegib ...
Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer
In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...
Trifluridine/Tipiracil Survival Benefit for Patients With Metastatic Gastric Cancer Who Had or Had Not Undergone Prior Gastrectomy
In a subgroup analysis of the phase III TAGS trial (TAS-102 Gastric Study) reported in JAMA Oncology, David H. Ilson, MD, PhD, and colleagues found positive trends in survival benefit with trifluridine/tipiracil treatment vs placebo for patients with pretreated metastatic gastric cancer or...
Conquerors Circle Recognizes Donors
The Conquerors Circle is Conquer Cancer, the ASCO Foundation’s appreciation society for donors who contribute $1,000 annually. In recognition of their generous and loyal support, Conquerors Circle members receive special recognition, which includes exclusive offerings for the ASCO Annual Meeting....
Why Do You Live to Conquer Cancer?
Oncologists are a special breed of physician who enter a patient’s life during one of the most distressing and often traumatic life experiences: a cancer diagnosis. That’s just the start of the journey, which can last many years and involve great successes and disappointments. This unique...
Leave a Legacy of Hope
By including a planned gift to Conquer Cancer ®, the ASCO Foundation, in your estate plans, you can help make a dramatic difference for patients with cancer years into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
Top Research From 2019 Quality Care Symposium Focuses on Cost of Cancer Care, Patient Participation in Clinical Trials
The 2019 Quality Care Symposium took place September 6–7, 2019, in San Diego. Abstracts presented at the symposium focused on efforts to improve the quality of care for patients with cancer. Highlights from this year’s meeting included research on the cost of care and patient participation in...
ASCO’s Journal of Global Oncology Informs Cancer Care Everywhere
As part of ASCO’s commitment to improving cancer care delivery and outcomes around the world, it publishes the Journal of Global Oncology (JGO). JGO Editorial Board member Lawrence N. Shulman, MD, has been a proponent of global thinking and global action in cancer care throughout his career. Dr....
Support Your Patients With ASCO Answers Fact Sheets
Direct, easy to understand, and in a convenient single-page format, ASCO Answers fact sheets introduce patients and their caregivers to types of cancer and cancer-related topics, including diagnosis, treatment, and side effects. Each fact sheet includes a topic overview, illustration, methods for...
How Cancer.Net Is Changing to Help Young Adults and Teenagers With Cancer
A diagnosis of cancer always comes as a surprise. Life does not prepare any of us for telling our friends and family that we have cancer, and this can be especially difficult for young adults and teenagers. Cancer interrupts their lives at a time when it is least expected. Life goals,...
Vipul Patel, MD, and Craig Reynolds, MD, Join AON Board
The American Oncology Network, LLC (AON), whose mission is to support the long-term viability of community oncology, has named Vipul Patel, MD, and Craig Reynolds, MD, to its Board. The AON Board provides strategic guidance to its growing network of physicians and physician practices, currently in...
Asciminib/Imatinib in Patients With Previously Treated CML
In a phase I trial, the combination of the BCR-ABL1 inhibitor asciminib and the small-molecule kinase inhibitor imatinib showed preliminary efficacy, safety, and tolerability in patients with chronic myeloid leukemia (CML) resistant to or intolerant of treatment with two or more prior tyrosine...
A Pioneer in Breast Cancer Clinical Trials, Norman Wolmark, MD, FACS, Looks Back on His Practice-Changing Accomplishments
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with breast cancer...
Long-Term Survival Outcomes With New Treatments for Advanced Melanoma: Questions Still in Need of Answers
The major treatment advances for melanoma can be attributed to anti–-cytotoxic T-lymphocyte–associated protein 4 (anti–CTLA-4; ipilimumab) and anti–programmed cell death protein 1 (anti–PD-1; nivolumab, pembrolizumab) immune checkpoint inhibitors and the combination of BRAF and MEK inhibitors...
Susan G. Komen Names Three Recipients of the 2019 Brinker Awards for Scientific Distinction
Susan G. Komen recently named Jane Visvader, PhD; George Lindeman, MBBS, PhD; and Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP, as this year’s recipients of the Brinker Awards for Scientific Distinction. The 2019 Brinker Award winners will deliver keynote lectures at the upcoming 2019 San Antonio ...
Dana-Farber Cancer Institute Receives $5 Million Gift to Create the Center for Myelodysplastic Syndromes
A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Dana-Farber Cancer Institute. The gift will help Dana-Farber in transformative collaborative research aimed at treating, preventing, and ultimately curing MDS....
FDA Issues Drug Safety Communication on Lung Inflammation Linked to Treatment With CDK4/6 Inhibitors
On September 13, the U.S. Food and Drug Administration (FDA) issued a drug safety communication warning that palbociclib, ribociclib, and abemaciclib—used to treat some patients with advanced breast cancer—may cause rare but severe inflammation of the lungs. The agency approved new warnings about...
Friends of Cancer Research Hosts Annual Leadership Awards
On September 24, 2019, Friends of Cancer Research (Friends) hosted its 23rd Annual Cancer Leadership Awards Reception. The event honored individuals who have been champions of cancer research and steadfast advocates for patients: Anna Barker, MA, PhD, Professor and Director, Transformative...
ASTRO Honors 2019 Gold Medalists, Honorary Member, and Other Award Recipients
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2019 Gold Medal awards and other high-profile honors at the 2019ASTRO Annual Meeting in Chicago. Gold Medalists Walter J. Curran Jr, MD; Silvia C. Formenti, MD, FASTRO; and Thomas R. Mackie, PhD, were awarded the...
$5 Million Gift to Advance Ovarian Cancer Research
The chairman emeritus of The Estée Lauder Companies has made a $5 million gift to the University of Arizona Cancer Center. The gift from Leonard A. Lauder supports the clinical and translational research of David S. Alberts, MD, an expert in the field of ovarian cancer research and treatment. Dr....
FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to trastuzumab deruxtecan for the treatment of HER2-positive metastatic breast cancer; granted Fast Track designation for bemcentinib for elderly patients with relapsed acute myeloid leukemia (AML); granted Breakthrough...
A Clinical Trial Was the Right Choice for Me
Nothing prepared me for a diagnosis of diffuse large B-cell lymphoma (DLBCL) in the fall of 2016. I had none of the typical symptoms of the cancer, such as night sweats, enlarged lymph nodes, or fatigue. In fact, my energy level was as high as ever, as I traveled around the country for business,...
Salk Scientist Tony Hunter, PhD, Receives National Cancer Institute Outstanding Investigator Award
Tony Hunter, PhD, a British-American biologist who is a Professor of Biology at the Salk Institute for Biological Studies, has received a National Cancer Institute (NCI) Outstanding Investigator Award, which supports accomplished leaders in cancer research. He will receive more than $7,500,000...
FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer
On October 23, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination...
Susan G. Komen Strengthens Advocacy Efforts With Launch of Komen Center for Public Policy
Susan G. Komen recently unveiled the Susan G. Komen Center for Public Policy, which is part of the organization’s growing efforts to fight for the interests of those impacted by breast cancer among state and federal policymakers. Through the Center, Komen will educate and mobilize breast cancer...
Health Insurance Literacy and Financial Hardship in Cancer Survivors
A new study published by Zhao et al in JNCI Cancer Spectrum has linked health insurance literacy with medical financial hardship as well as nonmedical financial sacrifices among adult cancer survivors in the United States. The study’s authors say the study indicated that health insurance literacy...
Addition of Trilaciclib to Chemotherapy in Metastatic Triple-Negative Breast Cancer
In a phase II trial reported in The Lancet Oncology, Tan et al found that the addition of the cell-cycle inhibitor trilaciclib to gemcitabine/carboplatin chemotherapy did not reduce the duration or incidence of severe neutropenia during chemotherapy in women with triple-negative breast cancer. A...
Factors in Genetic Testing Decisions Among Women With a Personal and Family History of Breast Cancer
In a study reported in the Journal of Oncology Practice, Scott et al identified several factors that motivated breast cancer survivors with high genetic risk to undergo genetic testing and found that clinicians often failed to discuss all relevant factors in decision-making. Study Details The...
Swallowing-Related Quality of Life After Radiotherapy vs Surgery for Oropharyngeal Squamous Cell Carcinoma
In the phase II ORATOR trial reported in The Lancet Oncology, Anthony Nichols, MD, and colleagues found a statistical but not clinically meaningful improvement in swallowing-related quality of life outcomes 1 year after treatment with radiotherapy vs transoral robotic surgery and neck dissection...
Addition of Induction Gemcitabine/Cisplatin to Chemoradiotherapy in Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The New England Journal of Medicine, Yuan Zhang, MD, PhD, and colleagues found that the addition of gemcitabine/cisplatin induction chemotherapy to standard platinum-based chemoradiotherapy improved recurrence-free survival vs chemoradiotherapy alone in...
Prior Antibiotic Treatment and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
In a study presented in a brief report in JAMA Oncology, David J. Pinato, MD, PhD, and colleagues found that past—but not concurrent—use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint inhibitors for various cancers in...
POLE/POLD1 Mutations and Outcomes With Immune Checkpoint Inhibitor Therapy
In a research letter published in JAMA Oncology, Feng Wang, MD, PhD, and colleagues identified the frequency of mutations in DNA polymerase epsilon (POLE) and delta 1 (POLD1) genes across cancer types and found that these mutations were associated with better survival outcomes among patients...
Fedratinib for Myelofibrosis
On August 16, 2019, fedratinib was approved for the treatment of adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1,2 Supporting Efficacy Data The approval was based on findings from the phase III double-blind...
Two New $1 Million Research Grants Focus on Metastasis of Melanoma
The American Cancer Society and Melanoma Research Alliance have selected two new promising projects in a second round of funding under a partnership between the two organizations. The first grants funded through the partnership, in 2018, focused on advancing research to reduce side effects...
National Clinical Trials Consultant, Linda L. Hogan, Dies at Age 72
Linda L. Hogan died on August 30, 2019, following a 25-year history of living with breast cancer and a more recent diagnosis of advanced lung cancer. She was born on November 29, 1946, in Farmington, Maine, and was the only child of Eleanor Sidell (Hogan) Stevens of Madison/Waterville, Maine, and...
Nab-paclitaxel/Gemcitabine/Cisplatin for Previously Untreated, Advanced Pancreatic Cancer
In a phase Ib/II pilot study reported in JAMA Oncology, Jameson et al found that treatment with nab-paclitaxel, gemcitabine, and cisplatin was active in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Study Details In the study, 25 patients were enrolled between...
Applying Results From CALGB (ALLIANCE)/SWOG 80405 Study
A recent study1 finding significantly longer progression-free survival and reduced risk for treatment-related toxicities among patients with metastatic colorectal cancer being treated with chemotherapy can have immediate application, albeit with some caveats related to the observational nature of...
Physical Activity Delays Disease Progression and Lowers Risk of Adverse Events in Patients With Metastatic Colorectal Cancer
Patients who were being treated with chemotherapy for metastatic colorectal cancer and who reported engaging in physical activity had a significantly longer progression-free survival and reduced risk for treatment-related adverse events than did those reporting less physical activity, according to...
The Art of Medicine: Our Role as Patient Advocates
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
City of Hope Enrolling Patients With Brain Tumors in First-of-Its-Kind Clinical Trial
City of Hope has opened a first-in-human clinical trial for patients with recurrent glioblastoma. The trial is the first to combine City of Hope’s chimeric antigen receptor (CAR) T cells that target the IL13Rα2 antigen common on brain tumor cells in combination with nivolumab and ipilimumab. To...
